INT127806

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2005
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 7
Disease Relevance 5.85
Pain Relevance 0.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (ASCL1) DNA binding (ASCL1)
ASCL1 (Homo sapiens)
Pain Link Frequency Relevance Heat
palliative 13 81.92 Quite High
metalloproteinase 8 5.00 Very Low Very Low Very Low
Sicca syndrome 2 5.00 Very Low Very Low Very Low
Somatostatin 2 5.00 Very Low Very Low Very Low
Glutamate 2 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
Serotonin 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Neuroendocrine Cancer 10 100.00 Very High Very High Very High
Carcinoid 27 99.84 Very High Very High Very High
Thyroid Neoplasm 498 98.44 Very High Very High Very High
Cancer 181 92.60 High High
Hyperplasia 3 92.40 High High
Neuroblastoma 2 88.80 High High
Manic Depressive Disorder 4 88.08 High High
Syndrome 8 81.52 Quite High
Disease 68 77.04 Quite High
Metastasis 44 73.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
inhibitors such as lithium chloride (LiCl) and SB216763 is associated with a significant decrease in neuroendocrine markers such as human-achaete-scute complex-like 1 (ASCL1) and chromogranin A (CgA).
Negative_regulation (decrease) of human-achaete-scute complex-like 1
1) Confidence 0.45 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621417 Disease Relevance 0.63 Pain Relevance 0
inhibitors such as lithium chloride (LiCl) and SB216763 is associated with a significant decrease in neuroendocrine markers such as human-achaete-scute complex-like 1 (ASCL1) and chromogranin A (CgA).
Negative_regulation (decrease) of ASCL1
2) Confidence 0.45 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621417 Disease Relevance 0.63 Pain Relevance 0
Furthermore, with Notch1 activation there was a concomitant decrease in ASCL1 in vitro, a downstream target of Notch1 signaling.
Negative_regulation (decrease) of ASCL1
3) Confidence 0.42 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2798103 Disease Relevance 1.02 Pain Relevance 0
Furthermore, SBHA treatment suppressed two neuroendocrine tumor markers, chromogranin A and achaete-scute complex-like 1.
Negative_regulation (suppressed) of achaete-scute complex-like 1 associated with neuroendocrine cancer
4) Confidence 0.39 Published 2007 Journal J. Gastrointest. Surg. Section Abstract Doc Link 17874277 Disease Relevance 1.12 Pain Relevance 0.08
We have recently shown that inactivation of GSK-3ß with lithium chloride (LiCl) and SB216763 results in MTC differentiation and cell growth inhibition; likewise, these small molecules have been shown to be associated with a significant decrease in NE markers such as human achaete-scute complex-like l (ASCL1) and chromogranin A (CgA) in cultured MTC cells [30].
Negative_regulation (decrease) of ASCL1 associated with thyroid neoplasm
5) Confidence 0.27 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2798103 Disease Relevance 0.76 Pain Relevance 0
Similar to its developmental role in the GI tract, Notch1 pathway activation led to an increase in hairy enhancer of split 1 (HES-1) protein and a concomitant silencing of human Notch1/HES-1/achaete-scute homolog 1.
Negative_regulation (silencing) of achaete-scute homolog 1
6) Confidence 0.25 Published 2005 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 16160079 Disease Relevance 0.70 Pain Relevance 0
Importantly, exposure to ZM336372 resulted in a significant reduction of bioactive hormone levels as well as the transcription factor, human achaete-scute homologue-1 in carcinoid tumor cells.
Negative_regulation (reduction) of achaete-scute homologue-1 associated with carcinoid
7) Confidence 0.17 Published 2005 Journal Mol. Cancer Ther. Section Abstract Doc Link 15956248 Disease Relevance 0.98 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox